Patient P-02643

Synthetic patientMETA-24 · Day 151 · 55–64 · F · baseline S14Open companion preview

Therapy response

Improving

Tolerance

Stable

GI state

Unstable

Inflammatory state

Unstable

Nutritional resilience

Unstable

Discontinuation risk

96%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events

solid = observed · dashed = predicted

Day 0 META-24 started — Baseline state S14
Day 47 NP-02 recommended — Dietary Support Protocol NP-02
Day 48 Patient accepted — Started NP-02 in the companion
Day 58 No meaningful change — Dietary Support Protocol NP-02
Day 71 Trajectory diverged from prediction — Observed response fell below the model's expected path.
Day 73 SC-12 recommended — Supportive Compound SC-12
Day 74 Patient accepted — Started SC-12 in the companion
Day 80 GI symptom burden −13% vs expected — Supportive Compound SC-12
Day 86 Tolerance state changed — Unstable → Improving

What changed?

Trajectory began diverging from predicted response on Day 71.

Primary contributors, last 14 days

GI instability+12
Inflammatory activity+11
Nutritional resilience-6
Treatment adherence-5

What helped?

Dietary Support Protocol NP-02Day 47
Result: no meaningful change
Supportive Compound SC-12Day 73
Result: symptom burden −13%

LIFE OS recommendation

GI Support Protocol GI-04

92%

probability of meaningful tolerance improvement

284 similar trajectories
87% showed improvement
median effect visible after 8 days

Biological layers

Which pathways look influenced, and by which layer of this person's biology.

Pathways under pressure

Butyrate / short-chain fatty acid production ↓80
- MicrobiomeButyrate capacity 43/100
- MicrobiomeF. prausnitzii depleted
- Daily logFibre intake low in recent food logs
Autonomic recovery ↓65
- WearableResting HR 83 bpm
- Wearable1,228 steps/day
- WearableShort sleep window
Mucosal barrier integrity ↓60
- DNAFUT2 non-secretor lowers mucosal fucosylation
- Daily logGI symptom score 65 and rising
- WearableSleep 5.7 h, below personal baseline
Inflammatory signalling ↑40
- BloodInflammatory load index 63
- WearableHRV 20 ms, trending down
Drug metabolism and exposure ↑20
- BloodToxicity index 57

DNA

Fictional pharmacogenomic panel

FUT2 rs601338 AA (non-secretor)
Reduced mucosal fucosylation
CYP2D6 Normal metabolizer
Expected exposure
GLP1R rs6923761 A
Altered receptor sensitivity

Microbiome

Shannon diversity 3 · butyrate capacity 43/100

Akkermansia muciniphilaNormal
Faecalibacterium prausnitziiLow
Bacteroides fragilisNormal
Bifidobacterium longumNormal
EnterobacteriaceaeHigh

Wearable, last 14 days

daily evolution fed into the runtime

HRV: 24 ms
Sleep: 5.8 h
Steps: 2,723
Resting HR: 85 bpm

Daily log: GI score 65, nutritional resilience 36, adherence 44.

What this patient sees in NostraAI

The content that steers the trajectory: what to eat, what to do, what to take.

Open companion preview

What to eat

Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
Eat slowly and stop at comfortable fullness — smaller volume, more often

What to do

Track each bowel movement today: time, stool form, urgency, overnight waking
A 15-minute walk after lunch
Protect a 7.5-hour sleep window; screens off 30 minutes before
Keep hydration steady: small amounts through the day rather than large volumes at once

What to take

Take the dose at the same time relative to your evening meal
Electrolyte solution, one sachet after any loose stool
Fictional demo item: oral nutrition supplement with lunch

284 biologically similar trajectories

Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

Patient	Similarity	Baseline	Intervention	Outcome	Response today
P-02118	53%	S14	GI-04	improved	47
P-02648	53%	S14	SC-12	improved	47
P-02348	52%	S14	GI-04	improved	49
P-02320	51%	S14	NP-02	improved	50
P-02574	50%	S14	ME-01	improved	45
P-02132	49%	S14	SC-12	improved	40
P-02363	49%	S14	GI-04	improved	49
P-02297	48%	S02	NP-02	improved	49
P-02057	47%	S14	GI-04	improved	47
P-02505	47%	S14	NP-02	improved	45
P-02582	47%	S14	ME-01	improved	45
P-02159	46%	S14	GI-04	improved	47